Oxford Biomedica (OXB), a prominent CDMO specializing in cell and gene therapies, has finalized a licensing and option agreement with the Viral Vector Manufacturing Facility (VVMF). VVMF operates Australia’s inaugural commercial-scale viral vector production site.
Core components of the agreement This five-year pact solidifies the non-binding terms reached in October 2025. Key highlights include:
-
Technology Transfer: VVMF gains a worldwide, non-exclusive license to OXB’s inAAVate manufacturing platform. Furthermore, VVMF holds an option to license the LentiVector technology.
-
Commercial Terms: OXB will receive an upfront payment in the low single-digit millions and is eligible for additional fees linked to the ongoing utilization of these platforms.
Strategic outlook for the APAC region This collaboration serves as a catalyst for VVMF to accelerate its operational readiness and align its processes with recognized global industry standards. For OXB, the partnership provides a vital strategic foothold in the Australian market.
Executives from both companies emphasized that this alliance is designed to address the surging demand for viral vectors across the Asia-Pacific (APAC) region. By leveraging OXB’s specialized expertise and internationally recognized platforms, VVMF aims to establish a leadership position in providing reliable and scalable manufacturing solutions for gene therapies in the region.
Source: https://www.contractpharma.com/breaking-news/oxford-biomedica-signs-licensing-deal-with-australias-vvmf/